Top Markets
Coin of the day
Aceragen, Inc. Aceragen, Inc.

Aceragen, Inc.

ACGN
Peringkat dalam Saham #39036
Aceragen, Inc., a biopharmaceutical firm in its clinical development phase,... Aceragen, Inc., a biopharmaceutical firm in its clinical development phase, operates out of Exton, Pennsylvania, and was founded in 1989. The company, which transitioned from Idera Pharmaceuticals, Inc. and adopted its current name in January 2023, concentrates on the discovery, advancement, and bringing to market of therapeutic agents for uncommon lung and autoimmune conditions exclusively within the United States. Its product development pipeline includes ACG-701, currently undergoing Phase 2 clinical evaluation for both cystic fibrosis pulmonary exacerbations and melioidosis, as well as ACG-801, which is being developed to address Farber disease. Moreover, Aceragen maintains a partnership and option agreement with Scriptr Global, Inc. This collaboration aims to pinpoint, research, and cultivate gene therapy options intended for the management, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia.
Harga Saham
$0.38
Terakhir disinkronkan: 2023-09-01
Kapitalisasi Pasar
$677.16K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Aceragen, Inc. (ACGN)

Kategori

Riwayat dividen untuk Aceragen, Inc. (ACGN)
Saham Aceragen, Inc. (simbol: ACGN) telah membayar total 0 dividen.
Total semua dividen (disesuaikan dengan stock split): 0.00
Imbal hasil dividen (TTM): 0
Pembayaran dividen untuk Aceragen, Inc. (ACGN) dari 2026 hingga 2026
Pembayaran dividen tahunan
Tahun Dividen (disesuaikan dengan stock split) Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Daftar semua pembayaran dividen
Tahun Dividen Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Pembayaran dividen untuk perusahaan sejenis atau pesaing
Perusahaan Jumlah pembayaran dividen Negara
0.00%
US
0.00%
NL
0.00%
CH
0.00%
KR
29.00%
BE